Success Metrics

Active Trials
2(100%)

Phase Distribution

Ph phase_1
1
50%
Ph phase_2
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

recruiting2100%

Recent Activity

2 active trials
Showing 2 of 2
recruitingphase_1

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

NCT06504381
recruitingphase_2

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

NCT06264388

Clinical Trials (2)

Showing 2 of 2 trials
NCT06504381Phase 1

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

Recruiting
NCT06264388Phase 2

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
2